BioSpace News Archive

Bryn Pharma, LLC announced today that three abstracts will be presented during the 2024 American Academy of Allergy, Asthma and Immunology (AAAAI).

BioIVT announced it has increased its capacity to deliver readily-available fresh, standard and mobilized, human leukopaks.

ReNAgade Therapeutics today announced that Amit D. Munshi, Chief Executive Officer, will virtually present at the Evercore ISI 2024 Emerging Biotech Conference on Thursday, February 29, 2024, at 9:35 a.m. ET.

Tenon Medical, Inc. announced that on February 15, 2024, the United States Patent and Trademark Office issued a Notice of Allowance for U.S. Patent Application Serial Number 18/107,536 for Tenon’s Catamaran® SI Joint implant for stabilizing a dysfunctional sacroiliac joint.

Kineta, Inc. announced today that it will present new preclinical data on KVA12123, the Company’s anti-VISTA antibody, in acute myeloid leukemia (AML) at the American Association for Cancer Research (AACR) Blood Cancer Discovery Symposium, to be held on March 4-6 in Boston, Massachusetts.

Umoja Biopharma, Inc. today announced that the company will participate in a Fireside Chat at the Evercore ISI 2024 Emerging Biotech Conference, taking place virtually on February 28-29, 2024.

Cosette Pharmaceuticals, Inc. (“Cosette”) announced that the U.S. Food and Drug Administration (FDA) has approved the Abbreviated New Drug Applications (ANDA) for the first generic version of RECTIV® (nitroglycerin) ointment, 0.4%, with 180 days Competitive Generic Therapy (CGT) exclusivity.

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT) today announced that the European Commission (EC), based on a positive opinion issued by the European Medicines Agency (EMA), has granted orphan medicinal product designation for the Company’s product candidate ARCT-032 to treat Cystic Fibrosis (CF).

Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (“Alpha Cognition” (ACI), or the “Company”) is pleased to announce that it has filed a new composition-of-matter patent that secures broad protection for its lead asset, ALPHA-1062, currently under review by the FDA for mild-to-moderate Alzheimer’s Disease.

Gracell Biotechnologies Inc. today announced the completion of its previously announced agreement to be acquired by AstraZeneca, in accordance with the terms and conditions of the Agreement and Plan of Merger, dated as of December 23, 2023.